Peter has more than twenty years of experience in drug discovery in the pharmaceutical industry. Prior to joining Epidarex, he was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the United Kingdom. He is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. Earlier in his career, Peter worked at Cancer Research UK and the Yamanouchi Research Institute (now Astellas) and served as Head of Biology at Karus Therapeutics. In addition to Topas Therapeutics, he currently serves on the Board of Directors of Caldan Therapeutics Ltd., Clyde Biosciences Ltd., Enterprise Therapeutics Ltd. and Mironid Ltd. He holds a BSc and PhD in biochemistry and molecular biology from the University of Leeds.